Oral drug administration is the most convenient and common for drug therapy and it is, therefore, very important and useful to estimate the absorbability of drugs and to predict the plasma concentration profile of drugs after oral administration for the development of novel drugs and/or novel dosage form and the designation of the dosage regimen. Generally, the absorbability of drugs has been estimated by in-situ recirculation studies, in-situ closed loop studies or the analysis by the simple compartment model. The information which can be obtained from these approaches is usually an absorption rate constant, ka. The ka value is generally the averaged one throughout the intestinal tract. However, there is the site-difference in drug absorbability [1] [2] [3] [4] and variable residence time of drugs in each segment must make the contribution of each segment to drug absorption changed, resulting in the different absorbability as a whole. As for the drug absorption after oral administration, the gastrointestinal (GI) transit of a drug is also an important factor to determine the drug absorption and is so variable, as was influenced by not only individual differences, 5) but also the dosage conditions like meals, 6) disease states 7) and so on. Therefore, the absorbability and the residence time in each segment are the major determining factors for drug absorption after oral administration and very important for the analysis of drug absorption kinetics and the estimation of, and the prediction of plasma concentration profiles of drugs. However, the analysis and the estimation of drug absorption after oral administration have been usually performed by a simple compartment model, where even a process of gastric emptying is not included often. This kind of simple model cannot describe the irregular shape in the plasma concentration, which is often observed. Therefore, several models were proposed to analyze the plasma profile, [8] [9] [10] [11] but they are not necessarily based on the practical phenomena, i.e. GI transit and site-different drug absorbability.
Generally, the absorbability of drugs has been estimated by in-situ recirculation studies, in-situ closed loop studies or the analysis by the simple compartment model. The information which can be obtained from these approaches is usually an absorption rate constant, ka. The ka value is generally the averaged one throughout the intestinal tract. However, there is the site-difference in drug absorbability [1] [2] [3] [4] and variable residence time of drugs in each segment must make the contribution of each segment to drug absorption changed, resulting in the different absorbability as a whole. As for the drug absorption after oral administration, the gastrointestinal (GI) transit of a drug is also an important factor to determine the drug absorption and is so variable, as was influenced by not only individual differences, 5) but also the dosage conditions like meals, 6) disease states 7) and so on. Therefore, the absorbability and the residence time in each segment are the major determining factors for drug absorption after oral administration and very important for the analysis of drug absorption kinetics and the estimation of, and the prediction of plasma concentration profiles of drugs. However, the analysis and the estimation of drug absorption after oral administration have been usually performed by a simple compartment model, where even a process of gastric emptying is not included often. This kind of simple model cannot describe the irregular shape in the plasma concentration, which is often observed. Therefore, several models were proposed to analyze the plasma profile, [8] [9] [10] [11] but they are not necessarily based on the practical phenomena, i.e. GI transit and site-different drug absorbability.
We have developed a GI-Transit-Absorption (GITA) Model containing the GI transit and absorption processes to analyze and predict the plasma concentration profile after oral administration of aqueous drug solution. 12) Although several efficient methods to estimate the absorption of orally administered drug by analyzing the GI disposition following oral administration (GI disposition analysis) have been reported, some are only focused on the gastric emptying based on a model having a stomach and an intestine compartment. 13, 14) The other one estimated the intestinal transit of a drug using polyethylene glycol 4000 as a nonabsorbable marker, 10) but the actual data of intestinal transit were not utilized enough to analyze and predict the drug absorption kinetics. Although the analytical procedures for plasma profile of a drug absorbed from successive absorption sites along the GI tract have been also reported, [16] [17] [18] they just showed the concept and/or simulation study based on the model. On the other hand, our method is simpler and can be easily applied to the analyses of various absorption behaviors. Furthermore, our model enables us to analyze and predict the plasma concentration after oral dosing based on the actual GI-transit pattern. Here, we would like to introduce the concept and the methodology of GITA Model, and to show its usefulness by reviewing the results obtained for the absorption kinetics of drugs with various characteristics. 12) To develop the GITA model, GI-tract was, first of all, divided into eight segments (stomach, duodenum, upper jejunum, lower jejunum, upper ileum, lower ileum, cecum and large intestine) and the transit of an unabsorbable drug from a segment to the next segment was approximated to follow a first-order kinetics as shown in Fig. 1 (GI Transit Kinetic (GITK) Model 12) ). The absorbable drug transits from a segment (i) to the next segment (iϩ1) with the segmental absorption (a first-order absorption) as shown in Fig. 2 (GITA Model 12) ). The absorption rate constant (ka i ) for each segment was determined by a conventional in-situ closed loop method 19, 20) and the GI transit rate constant (k i ) for each seg-ment was calculated by the in-vivo studies using phenol red, an unabsorbable marker.
GI-TRANSIT ABSORPTION (GITA) MODEL: THEO-RETICAL

12)
A) Absorption Kinetics Containing GI Transit and Absorption in Each Segment
If drug distribution in each intestinal segment can be defined as the well-stirred phase, the k i value represents the intestinal transit clearance that is hybrid parameter of the intestinal transit rate constant and the intestinal distribution volume for unit length. Further, the absorption in each segment is assumed to be the apparent firstorder process and the absorbability is represented by the absorption rate constant, which is supposed to be equivalent to the value obtained from dividing the absorption clearance by the intestinal distribution volume.
Gastric emptying rate and intestinal transit rate for each segment are represented by Eqs. 1 and 2, respectively, using an unabsorbable drug (ka i ϭ0). (1) where at tϭ0, X s =D p.o. (the dose of the orally administered drug). (2) where X, k and ka represent the amount, the transit rate constant and the absorption rate constant, respectively. The subscripts s and i for parameters show stomach and each intestinal site, respectively.
B) Prediction of Plasma Concentration Profile by Convolution Method
The outline of the prediction method using the convolution analysis is as follows.
In
Step 1, the amount of drug versus time profile (X-time profile) in each segment is calculated by means of the convolution method. Laplace transform of drug amount in segment iϩ1 (X iϩ1 (s)) is described by Eq. 3. (3) That is, the fraction of dose available for the absorption in segment iϩ1 (F iϩ1 ) can be given by Eq. 4 using its Laplace transform ( f˜i ϩ1 (s)). (4) In Step 2, the absorption rate versus time profile in each segment is calculated by using X-time profile obtained in Step 1 and the absorption rate constant in each segment. The fraction of dose absorbed (absolute absorption) from segment i (Fa i ) can be given by Eq. 5 using its Laplace transform ( f˜a i (s)).
Step 3, the total absorption rate-time profile in the whole GI tract is calculated as the sum of the absorption rate-time profiles obtained in Step 2.
In Step 4, the prediction of plasma concentration of orally administered drug is performed by means of the convolution method. The total absorption rate-time data obtained in Step 3 and pharmacokinetic parameters after intravenous administration correspond to the input function and the transfer function, respectively. Plasma concentrations (Cp) of model drugs after intravenous administration were analyzed by a two-compartment model using a nonlinear least-squares program, MULTI. 21) Laplace transform of the plasma concentration after oral administration (Cp (s)) as follows. (6) The inverse Laplace transformation of Eq. 6 gives the predicted drug concentration in plasma after oral administration without the first-pass elimination in intestinal epithelium and/or liver. 12) To investigate the GI transit of drugs after oral administration, phenol red, an unabsorbable marker, was orally administered into rats as an aqueous solution. Figure 3a shows the observed time course of phenol red recovery in each segment after oral administration. The fitting line (Fig. 3b) and the k i value (Table 1) for each segment (i) was calculated using a non-linear regression program, MULTI(FILT) 22) based on GITK model. The calculated curves for phenol red remaining in each segment were well fitted to the experimental data and the k i values were also consistent with the transit clearance in segment i (CLg i ) calculated by the equation: CLg i ϭ 100/AUCg i , the area under the curve of the observed recovery of phenol red dose (%) against time. These coincidences strongly suggest that the model does precisely describe the entire GI-transit process. Under the fasted state, the gastric emptying is reported to be almost completed by 1 h, and its half-life is to be approximately 0.15 h.
GI-TRANSIT KINETIC (GITK) MODEL AND ESTI-MATION OF GI TRANSIT
23) The gastric emptying rate estimated in this study was slightly lower and the half-life was 0.34 h. As is evident from the table, the k i value decreased along the intestinal tract from upper (28.75 h
Ϫ1
) to lower (0.46 h Ϫ1 ) region and the transit rate differs considerably in each segment, although it depends on the estimated intestinal length. Especially, the transit rates in the upper segments such as duodenum and upper jejunum were extremely high, but the ones in the lower segments such as upper and lower ileum were very low. This tendency in GI transit is in good agreement with the report by Marcus and Lengemann. 24) Small amount of phenol red appeared in cecum at 2 h after dosing, which corresponds to the GI transit time of drug in rats. 25) Furthermore, the large intestine has been found not to contribute to the drug absorption at least up to 10 h after oral administration, because phenol red was not detected up to 10 h post dosing. To estimate the contribution of the large intestine to drug absorption, further studies with longer term must be conducted. 12) Prediction studies were performed for four drugs with different absorption kinetics according to the procedure from Steps 1 to 4 described above. The first-order absorption rate constants of the tested drugs in the 8 segments are listed in Table 2 . Predicted plasma concentrations of four model drugs, ampicillin, theophylline, cephalexin and propranolol, after oral administration were finally calculated by convolution with the Eq. 6 using the parameters in Tables 1 and 2 .
PREDICTION OF PLASMA CONCENTRATION PRO-FILES FOR ORALLY ADMINISTERED DRUGS
Ampicillin was chosen as a model drug poorly absorbable from GI tract and having no first-pass elimination. 26) Plasma a) The k i value for each segment was obtained from the fitting of the experimental data in Fig. 3a to GITK Model ( Fig. 1 ) by using MULTI (FILT). 21) b) The k i value for each segment was calculated from AUCg i in each segment and represented as the mean value of 3 experiments. c) Not calculated. d ) As AUCg i in cecum will be much larger than the observed value, the substantial value of k i for cecum will be much smaller than the calculated value. (Cited from Sawamoto et al. Absorption rate constants were obtained from the conventional in-situ loop studies. a) Cited from Sawamoto et al. 12) b) Cited from Kimura et al. 34) c) Not examined.
concentrations of this drug after oral administration reflect only the absorption from whole GI tract and the systemic elimination. As shown in Fig. 4A , the predicted curve for ampicillin agrees well with the experimental result. Pharmacokinetic parameters calculated from the predicted plasma concentration profile are similar to those calculated from the experimental data (Table 3) . Theophylline was examined as a drug absorbed rapidly from the GI tract. Theophylline is characterized as a well-absorbable drug without first-pass elimination. 27) Predicted plasma concentration profile of theophylline after oral administration as aminophylline showed the good-fitted profile (Fig. 4B ). As shown in Table 3 , pharmacokinetic parameters calculated from the predicted profile are consistent with those calculated from the experimental data.
To assess the utility of this method in the case of a drug absorbed via carrier-mediated transport system, [28] [29] [30] the absorption of cephalexin was examined. Cephalexin is characterized as a well-absorbable and hepatic non-extractable drug. 31) Assuming the first-order absorption in the model, the predicted plasma concentration and the pharmacokinetic parameters of cephalexin are in good agreement with the observed data ( Fig. 4C and Table 3) .
It is well known that orally administered propranolol is biotransformed by the pre-systemic metabolism. 32) Figure 4D shows the predicted profile and observed data of the plasma concentration of propranolol. Since this prediction method gives the AUC value of drug without the first-pass elimination, the difference between the predicted and the observed values of AUC represents the contribution of the first-pass elimination. The ratio of the first-pass elimination was predicted as 70% (Table 3) , corresponding to the reported value (70-80% 32) ). By using this method, the amount of a drug in each seg- 12) b) Cited from Kimura et al. 34) 
). e) F int,h ϭF/F abs . f ) Based on GITA Model with hepatic first-pass metabolism process. ment after oral administration can be calculated as Eq. 4. Figures 5A and 6B show the calculated time courses of the amount of theophylline and ampicillin in each segment after oral administration, respectively. As is evident from the figure, theophylline disappears rapidly from the GI lumen and only a little amount reaches the ileum. Substantial absorption rates of theophylline are found to be much larger in the upper segment than those in the lower segments, and the duodenum, upper jejunum and lower jejunum largely contribute to the absorption of theophylline (Fig. 5B ). On the other hand, a large amount of ampicillin, a poorly absorbable drug, can reach the lower intestine and almost 70% of the dose can enter the cecum (Fig. 6A) . From the absorption rate profile for ampicillin in each segment (Fig. 6B ), the site of the largest absorption is clarified to be the lower jejunum. Although the residence time is longer and the drug amount is larger in the lower intestine compared to the upper segments, the actual absorption rate is not the largest because of a small ka value in the ileum.
The substantial contribution of each segment to the cephalexin absorption in-vivo is summarized with k i and ka i values of each segment in Fig. 7 . The ka i values of cephalexin obtained by an in-situ loop method (Table 2) were larger in the upper small intestine than in the lower region, indicating that the preferential absorption site was considered to be the upper part as has been reported previously. 33) However, as the residence time in the upper small intestine is very short, the substantial absorption site of cephalexin in-vivo is shifted to below lower jejunum in the fasted state (Fig. 7) . It should be noted that the transit rate, or the residence time, in each site could change the substantial absorption site in-vivo. Segmental absorption, ; GI transit rate constants, ᭹; absorption rate constants, ᭺. ᮀ
PREDICTION OF PLASMA CONCENTRATION PRO-FILE FOR A DRUG SUBJECTED TO HEPATIC FIRST-PASS METABOLISM 34)
N-Methyltyramine (NMT) is known as a potent stimulant of gastrin release and has been reported to be present in beer. 35) As NMT was found to be subjected to the hepatic first-pass metabolism in the process of examining its absorption kinetics, we tried to introduce the process of the hepatic first-pass elimination to GITA model and to predict the plasma concentration-time profile of NMT after oral administration to rats. The prediction was performed by the same method as described above using k i and ka i values listed in Tables 1 and 2 , respectively. Dotted line in Fig. 8 shows the predicted plasma concentration-time curve for NMT after oral administration at the dose of 20 mg/kg, based on GITA model without the first-pass elimination process and the fraction absorbed was estimated to be 0.974 from its AUC value. The predicted curve was higher than the observed data, suggesting that NMT should be subjected to the first-pass metabolism or presystemic elimination in the small intestine and/or liver. The result of in-vitro experiments using the homogenate of rat small-intestinal mucosa or liver showed the marked metabolism of NMT in the liver, but the negligible metabolism in the small-intestinal mucosa, indicating that the first-pass metabolism of NMT would occur mainly in the liver. The rate of metabolism of NMT in the 1000ϫg supernatant of liver homogenate was estimated in-vitro and the hepatic availability (F h ) was calculated according to the following equation.
36) (7) where Q h , f p , R B and CL int,h mean the hepatic (portal) blood flow, the unbound fraction in plasma, the blood-to-plasma concentration ratio and the hepatic intrinsic clearance, respectively. CL int,h was calculated by the following equation:
ϫprotein amount in the supernatant (mg/g liver)ϫliver weight (g)
Kinetic study on the hepatic metabolism showed the linearity of its metabolism in the range of initial concentration (0-5 mM) and the hepatic intrinsic clearance (CL int,h ) was calculated to be 2043Ϯ55 ml/h. Then the hepatic availability (F h ) was calculated to be 0.510, 34) using f p (0.423Ϯ0.003), R B (1.53Ϯ0.08) and Q h , 588 ml/h. 37) Introducing the F h value into GITA Model made it possible to predict the plasma concentration-time profile for orally administered NMT very well, 34) as shown in Fig. 8 and Table 3 . The results obtained for NMT indicate that GITA Model with the hepatic first-pass metabolism process can predict the plasma concentration-time curve of drugs subject to the hepatic first-pass metabolism after oral administration. 38, 39) The effect of GI transit rate on the absorption behavior of orally administered drugs was investigated using rats pretreated with propantheline 38) or loperamide. 39) The k i values for each segment in rats pretreated with propantheline or loperamide are summarized in Table 4 . Propantheline, one of the synthetic substitutes for belladonna alkaloids, can reduce tone and motility of GI-tract as a muscarinic receptor antagonist. 40) Loperamide, a piperidine derivative, is known to slow the intestinal motility by effects on the circular and longitudinal muscles of the intestine, presumably as a result of its interactions with opioid receptors in the intestine. 41) The results indicate that the pretreatment with propantheline reduced not only the gastric emptying rate but also transit rates in all the small intestine to about a half of the corresponding values in normal rats. 32) On the other hand, the pretreatment with loperamide reduced the intestinal transit rate without affecting the gastric emptying rate.
ABSORPTION BEHAVIOR OF ORALLY ADMINIS-TERED DRUGS IN GI TRANSIT-RETARDED RATS
33) The effect of retarded GI transit rate on the absorption behavior of orally administered drugs was examined for theophylline, ampicillin and cephalexin. Propantheline (loperamide) was administered intraperitoneally (intragastrically) at 2.5 mg/kg (1.0 mg/kg) 2 h (0.5 h) prior to oral administration of phenol red solution. The k i values were obtained by the fitting study using MULTI (FILT). 21) a) Cited from Sawamoto et al. 12) b) Cited from Haruta et al. 38) c) Not calculated. Since pharmacokinetics of theophylline was changed by the treatment with propantheline or loperamide, the pharmacokinetic parameters after intravenous administration to rats treated with propantheline or loperamide, which are shown in the footnote of Table 5 , were used as the weight function and for estimating the bioavailability. Figure 9A shows the plasma concentration profiles of theophylline after oral administration of aminophylline in rats pretreated with propantheline, together with the result in normal rats, and the pharmacokinetic parameters are summarized in Table 5 . 38) As is evident from the figure, the retardation of GI transit rate containing the gastric emptying rate resulted in the change in T max (from 0.40 to 0.85 h) of theophylline. The decrease in the plasma concentration and AUC of theophylline might be attributed mainly to the increase in its distribution volume, of which the reason remains to be clarified. However, the extent of bioavailability for theophylline was hardly changed by the retardation of GI transit as shown in Table 5 . Although intestinal transit rate also decreased in the present study, it can be considered that the change in the absorption profile should reflect the retarded gastric emptying rate by propantheline. Since theophylline is rapidly absorbed and the absorbability is not so different among the segments of small intestine, the intestinal transit retardation doesn't affect its absorption profile. Figure 9A also shows the plasma concentration profiles of theophylline after oral administration of aminophylline in rats pretreated with loperamide, and the pharmacokinetic parameters are summarized in Table 5 . As is evident from the figure, the retardation of GI transit rate except the gastric emptying rate resulted in no change in T max of theophylline. Although the plasma concentration, therefore, AUC of theophylline decreased, loperamide did also increase the distribution volume of theophylline, of which the reason remains to be clarified as well. This case also indicated that the extent of bioavailability was hardly changed by the retardation of the intestinal transit. 39) The low bioavailability of ampicillin is caused by the low absolute absorption but not by the first-pass elimination. Accordingly, the bioavailability of this kind of drugs would be able to be improved by reducing the GI transit rate, i.e., increasing the residence time in the small intestine, which will give the drugs more opportunity to be absorbed. Figure 9B shows the plasma concentration profile of ampicillin after oral administration in rats pretreated with propantheline. 38) The pharmacokinetic parameters are listed in Table 5 . As expected, it is evident that the extent of bioavailability was increased up to almost twice by the prolongation of the residence time in the GI tract in rats pretreated with propantheline. The T max was longer in the GI transit-retarded rats (1.33 h) compared to the normal rats (0.75 h). The delayed T max of ampicillin can be explained by the decreased gastric emptying rate, as indicated in the case of theophylline. The prediction study for ampicillin, assuming 50% reduction of gastric emptying rate with no change in the intestinal transit rate, resulted in the delayed T max but no change in the extent of bioavailability (result not shown). Thus, the delay of T max and the increase in the extent of bioavailability of ampicillin in rats pretreated with propantheline might be due to the delayed gastric emptying rate and the prolonged residence time in the small intestine, respectively. Figure 9B also shows the plasma concentration profile of ampicillin after oral administration in rats pretreated with loperamide, and the pharmacokinetic parameters are listed in Table 5 . The extent of bioavailability was increased up to almost twice, with no change in the T max , by the prolongation of the residence time in the intestinal tract in rats pretreated with loperamide. 39) The importance of the residence time in the absorption site Results shown here are observed data expressed as the mean value of at least three experiments. Equations describing the plasma concentration of theophylline after intravenous administration of aminophylline (5 mg/kg) are as follows: for control rats, Cpϭ17.5 · exp(Ϫ14.2 · t)ϩ11.8 · exp(Ϫ0.40 · t) (mg/ml); for rats treated with propantheline, Cpϭ7.1 · exp(Ϫ15.9 · t)ϩ9.2 · exp(Ϫ0.40 · t) (mg/ml); for rats treated with loperamide, Cpϭ4.3 · exp(Ϫ3.2 · t)ϩ6.0 · exp(Ϫ0.29 · t) (mg/ml). a) Cited from Haruta et al. 38) for the bioavailability was confirmed, especially for poorly absorbable drugs.
Effects of GI-transit retardation on cephalexin absorption was also examined by rats treated with propantheline and the results are summarized in Fig. 10 . The figure shows that much higher transit rate in upper small intestine than that in lower one resulted in the shift of the substantial absorption site of cephalexin in-vivo from upper small intestine (Table  2) to below lower jejunum in the fasted state. Similarly, the amount absorbed in each segment after oral administration was calculated in rats pretreated with propantheline (Fig.  10) . 38) As is evident from the figure, the substantial absorption site moved to upper region. Although this change in substantial absorption site will occur for other drugs, the shift is predominant for cephalexin, because the antibiotic is absorbed via carrier-mediated transport system in upper segments more efficiently. These results strongly indicate that the transit rate or the residence time in the site of absorption is an important factor determining the extent of absorption in each site in-vivo. 42) To evaluate the GI transit rate for each segment in-vivo, a non-invasive technique, gamma scintigraphy, [43] [44] [45] [46] [47] [48] [49] [50] was employed using unabsorbable compound, Tc-labeled diethylenetriamine-pentaacetic acid (DTPA) 42) with a gamma camera system (PRISM 3000-Odyssay, Picker International Inc., Cleveland, OH, U.S.A.). Using gamma scintigraphic technique, it is possible to simultaneously evaluate the GI transit and absorption of orally administered drug in the same individual. Theophylline was simultaneously administered along with Tc-DTPA (0.4-0.5 mCi/body) under the fasted and fed states. The dosed rat in the restraining cage was kept on the scintillation camera. The gamma scintigraphic imaging started just after dosing and was carried out for 6 h at 2-min intervals under the dynamic planar condition. GI tract was divided into four segments, i.e., stomach (s), jejunum (jej), ileum (ile), cecum and below (ce) (Fig. 10) , because it was difficult to distinguish the upper part from the lower of jejunum or ileum by gamma scintigraphic images. The radioactivity in each segment was then measured in each region of interest (ROI) using NIH Image program (http://rsb.info.nih.gov/nihimage/), and the relative percent of radioactivity in each ROI was plotted against time. The fitting line and the k i value for each segment was calculated using a non-linear regression program, MULTI (FILT) 22) based on GITK model according to the same procedure described in theoretical section, but a lag time factor in the ileo-cecal region was introduced into GITK model here, because there is a valve, which would contribute to gut homeostasis by optimizing retention of chyme in the small intestine until digestion is complete. 51) An absorbable drug transits from a segment to the next segment with segmental absorption (first-order absorption). Gastric emptying rate and transit rate for each segment are represented by the Eqs. 1 and 8 to 10, by substituting zero for ka i in the case of unabsorbable drug like 99m Tc-DTPA, which is corresponding to GITK Model.
APPLICATION OF GAMMA SCINTIGRAPHY TO GI TRANSIT MONITORING
For stomach: (1) where at tϭ0, X s ϭD p.o. (the dose of the orally administered drug). For jejunum: (8) For ileum:
(t Ն T lag )
For cecum/colon:
where X, k and ka represent the amount, the transit rate constant and the absorption rate constant, respectively. T lag represents an onset time when the dug transits from the ileum to cecum in the ileo-cecal region. The subscripts for parameters
Fig. 10. Effect of GI Transit Retardation on Substantial Absorption Site of Cephalexin after Oral Administration in Fasted Rats
Segmental absorption: control rats, shaded bar; rats treated with propantheline, open bar. GI transit rate constants: control, ᭹; treated with propantheline, ᭺. (Cited from Haruta et al., 38) with permission from John Wiley & Sons, Inc.).
Fig. 11. Modified GITA Model
A modified GITA Model is a pharmacokinetic model, which consists of four segments and contains a GI transit and an absorption process in each segment. D, initially administered dose; X i , amount of drug in the segment i; k i , first-order transit rate constant from the segment i; ka i , first-order absorption rate constant for the segment i; T lag , onset time to transit from the ileum to cecum; k el , first-order elimination rate constant from central compartment; F, bioavailability without first-pass elimination.
mean each GI site.
The prediction of the plasma concentration-time curve by convolution method consists of four step analyses as described above. The predicted profile represents the plasma concentration profile without the first-pass elimination in intestinal epithelium and/or liver. Figure 12 shows typical gamma scintigraphic images of 99m Tc-DTPA passing through rat GI tract post dose. 42) Orally administered 99m Tc-DTPA was confirmed to periodically migrate below along the GI tract. Figure 13 shows both of observed time courses of the relative percent of radioactivity in each segment by the gamma scintigraphic study and theoretical curves based on GITK Model under each feeding condition in a rat. 42) Since a lag time is clearly observed in the transit process from the ileum to the cecum in every study, the lag time was introduced in the GITK Model. The similar lag time was observed in our human study shown below. The necessity of a lag time means that it is difficult to describe the transit kinetics in ileum by a single well-stirred compartment. As is, however, evident from the figure, the theoretical curve of radioactivity for each segment, which was obtained from the fitting analysis, was in good agreement with the observed data in each individual study. This result indicates that GITA Model which consists of four GI segments with a lag time factor in the ileo-cecal region could be practically useful. The corresponding GI transit parameters in three rats are summarized in Table 6 . GI transit rate constants for stomach 
4.17
The gastrointestinal transit rate constant for each segment and a lag time in the ileocecal region were obtained from the fitting of the experimental data to GI-Transit Kinetic Model. a) CLg i , the transit clearance in segment i, was calculated by 100/AUCR 0-12 h . AUCR 0-12 h means the area under the percent of dosed total radioactivity versus time curve for each segment calculated by the trapezoidal rule. b) Not calculated. (Reproduced from Haruta et al. 42) with permission from John Wiley & Sons, Inc.) total radioactivity versus time curve from 0 to 12 h after dosing. 12) However, in the case of ileum, larger values of k ile than CLg i of ileum were given in 4 of 6 cases because of introducing a lag time factor to the ileo-cecal region, which means CLg i should be utilized to discuss the intestinal transit of drug in this study. Although the introduction of lag-time factor to GITA Model sometimes allowed us to overestimate k i values, they have been also found to be quite useful practically for the description of the GI transit of drug after oral administration.
GI transit behavior was remarkably affected by the different food conditions. Under the fasted condition, every gastric emptying of 99m Tc-DTPA completed by 1-h post dose for all three rats examined. And then almost the entire dosed marker has reached the cecum within 4 h. In contrast, under the fed condition gastric emptying rate constants significantly decreased to 0.35 to 3.92 h Ϫ1 (1.01Ϯ1.07 h
Ϫ1
, pϽ0.05), and in 2 of 3 cases the gastric emptying did not complete even 6-h post dose, resulting in the prolongation of the time for all the marker dosed to reach the cecum. The same tendency was found for the transit in jejunum and ileum, although we have to discuss the transit along the small intestine by employing the values of CLg i as described above.
CLg i shows the larger and the smaller values in stomach and jejunum, respectively than those in Table 1 . For the reasons, there are some possible explanations as follows: 1. Different compartment models were employed. 2. Rats were kept in the different types of the restraining cages. 3. Different unabsorbable markers were utilized. 4. The parameters in Table 1 were obtained from the averaged values including a large inter-individual variance, while Table 6 gave the parameter for each individual subject. Although we need to figure out which factor would influence predominantly GI transit of drug, it should be taken into consideration that GI transit might be changed easily by some factors even under the fasted condition.
The plasma concentration-time curve of theophylline after oral administration of aminophylline was estimated for each rat using GI transit rate constants determined above for each rat in the fasted and fed conditions, according to our prediction method. The results are shown in Fig. 14, together with the observed data.
42) The predicted curves were in good agreement with observed data in all the individual studies. As shown in Table 7 , T max and Cp max for theophylline, which were well predicted by GITA Model, were remarkably influenced by the presence of food. This effect on the plasma concentration-time curve is caused by the alteration of GI transit behavior, mainly gastric emptying. The delay of gastric emptying by ingested foods was also reported to cause the delay of the absorption of several drugs, including theophylline in human. 52, 53) The analysis using GITA Model and gamma scintigraphic technique made it possible to estimate the variable absorption kinetics regulated by the GI transit with a huge variability. The plasma concentration-time profile of theophylline after oral administration in human volunteers was predicted using the individual GI transit data monitored by a gamma scintigraphic technique. Theophylline was administered as aminophylline, along with Tc-labeled DTPA to evaluate the GI transit by a gamma scintigraphic technique as described above.
The study was performed for each subject under two different food conditions at an interval of a month. Under the fasted condition, each subject was dosed after a 12-h overnight fast. While, under the fed condition, each subject was dosed 1 h after a light breakfast consisting of a slice of bread, a scrambled egg, two boiled sausages and a glass of orange juice. Food was withheld for at least 5 h after the drug administration. Under each food condition, aminophylline (100 mg) was administered as the 30 ml of aqueous solution containing 99m Tc-DTPA (4-5 mCi), followed by 70 ml of water. After the drug dosing, imaging was immediately undertaken with a subject on his back using a gamma camera. The gamma scintigraphic imaging was carried out for 480 min. For the first 60 min, imaging was continuously carried out at 2-min intervals under the dynamic planar condition, beginning immediately after dosing, and then imaging was carried out for 2 min each after 90, 120, 150, 180, 240, 300, 360, 420 and 480 min under the static planar condition. During the non-imaging time, subjects were allowed to free action.
GI tract was divided into four segments, i.e., stomach (s), jejunum (jej), ileum (ile) and cecum/colon (co) in the same way as shown in Fig. 11 . The radioactivity in each segment was then measured from each ROI using a mini super computer (PRISM 3000-Odyssey), and the relative percent of radioactivity for each ROI versus time was generated. The GI transit rate constant (k i ) for each segment in the individual study was obtained from the fitting of the experimental GI transit data to the modified GITK Model incorporating a lag time factor in ileo-cecal region. Figure 15 shows the scintigraphic image of the whole GI tract, obtained by piling up each image of the GI tract acquired after oral administration of 99m Tc-DTPA, and each ROI located for four divided GI segments. Figure 16 shows both the observed time courses of the relative percent of radioactivity in each GI segment determined by the gamma scintigraphic study and the theoretical curves based on the modified GITK Model with a lag time factor in the ileo-cecal region. As is evident from the figure, the theoretical curve of radioactivity for each GI segment, which was obtained from the fitting analysis, was in good agreement with the observed data in all the individual studies. The corresponding GI transit parameters are summarized in Table 8 , and GI transit rate constants thus calculated have been found to be quite useful for the description of the GI transit of a drug after oral administration. However, the transit rate constants thus calculated merely for the ileum don't reflect the actual transit of drugs, because of introducing a lag time factor to the ileocecal region as is in the case of rats in Section 6. The GI transit clearance (CLg i ), therefore, was employed to discuss the GI transit, and the values are also summarized in Table 8 . Under the fasted condition, the gastric emptying of the radioactive marker in both subjects completed by 1-h post dose, resulting in the gastric emptying clearances of 4.62 and 4.24 h
. And once the radioactive marker began to enter the cecum at approximately 3-h post dose, the cecum and colon were very rapidly filled with the entire radioactive marker until 5-7 h post dose. On the other hand, under the fed condition, gastric emptying clearances decreased to 1.17 and 0.82 h Ϫ1 for each subject, resulting in the prolongation of the time for all of radioactive marker dosed to reach the cecum and colon. There is, however, no apparent effect of food on the transit parameters for the jejunum and ileum. This observation is supported with other report, where the food intake and dosed formulation delay the gastric emptying rate but not affect the small-intestinal transit rate. 5) To predict the plasma concentration-time curve after oral administration, the absorption rate constant of theophylline for each GI segment in human is needed. Although, in the rat study, absorption rate constants of theophylline were obtained by performing a conventional in-situ closed loop Predicted parameters were calculated from the data simulated by convolution method based on the GITA Model. T max and Cp max were defined as the time to reach the maximum plasma concentration and the maximum plasma concentration, respectively. (Reproduced from Haruta et al. 42) with permission from John Wiley & Sons, Inc.) method for each GI segment, it is hard to estimate directly the corresponding absorption parameter for each GI segment in human. Therefore, the absorption rate constants in human were calculated using the absorption rate constants of theophylline obtained in rats according to the relationship between the absorption rate constants in human (ka human ) and rats (ka rat ) reported by Yuasa. 55) The equation, ka human ϭ 0.744 · ka rat , was introduced from the difference in the surface area and luminal volume of the small intestine between human and rats, based on the relationship of the permeability between human and rat reported by Amidon et al. 56) The absorption rate constants obtained for human GI segments are as follows; stomach (unabsorbable), jejunum (8.84 h
) and ileum (6.01 h
). Then, the plasma concentration-time curve of theophylline after oral administration of aminophylline was estimated for each study using the ka values for human and individual GI transit rate constants in the fasted and fed conditions, based on GITA Model. The predicted plasma concentration-time curves of theophylline are shown in Fig.  17 , together with the observed data. The disposition parameters of theophylline after intravenous administration in human, which were used as a weight function in the convolution analysis, were data of 24 subjects cited from literatures. [57] [58] [59] The subjects consist of not only normal volunteers but also asthmatic subjects. But the authors showed that the pharmacokinetic parameters in the group of asthmatic subjects were not significantly different from those in the group of normal volunteers. 59) Considering the interindividual variation of the disposition parameters, the prediction was performed using three different sets of weight functions, i.e., pharmacokinetic parameters averaged for 24 subjects (Cpϭ2.15e Ϫ5.20t ϩ2.20e Ϫ0.15t ), the ones for the highest plasma profile (Cpϭ2.56e Ϫ6.19t ϩ1.90e Ϫ0.24t ) and the ones for the lowest plasma profile (Cpϭ0.13e Ϫ2.60t ϩ2.85e Ϫ0.11t ), which are normalized at the dose of 1 mg/kg. The plasma concentration-time curves predicted using the averaged parameters as the weight function are in good agreement with the observed data in all the individual studies. Lower Cp max and larger T max in the plasma concentration-time curves under the fed condition were observed than under the fasted condition (Fig. 17) . This effect of food conditions on the plasma concentration-time curve is caused by the alteration of the GI transit behavior, mainly gastric emptying. Higaki et al. 60) reported that the gastric motility was closely correlated with the gastric emptying under the fed condition when caffeine The GI transit rate constant for each segment and a lag time in the ileo-cecal region were obtained from the fitting of the experimental data to GI-Transit Kinetic Model. CLg i , the transit clearance in segment i, was calculated by 100/AUCR. AUCR means the area under the percent of dosed total radioactivity versus time curve for each segment calculated by the trapezoidal rule. a) Not calculated.
was orally administered as a small enteric coated pellet. Gastric motility is well known to show the migrating motor complex (MMC) under the fasted state, 61, 62) meaning MMC regulates the gastric emptying under the fasted condition. On the other hand, the gastric emptying is regulated by feedback mechanisms influenced by the contents in the duodenum, 62) resulting in the irregular contractions of the antrum. 63) Figure  18 shows the amount of theophylline versus time profiles in Theophylline was administered at the dose of 85 mg (100 mg)/body as aminophylline. Prediction of plasma concentration profile of theophylline after oral administration of aminophylline, which is shown by solid line, was performed using 3 different sets of weight functions, i.e., (a) pharmacokinetic parameters obtained from a subject with the lowest plasma profile, (b) pharmacokinetic parameters averaged from data of 24 subjects and (c) pharmacokinetic parameters obtained from a subject with the highest plasma profile after intravenous administration of theophylline. the stomach and small intestine, which were simulated using k i and ka i values obtained in the present study. This result indicates that the gastric emptying rate determines the absorption rate of theophylline. Therefore, a greater value of k s results in a greater absorption rate of theophylline, which is reflected by a higher Cp max and a smaller T max as a rate of bioavailability under the fasted condition. The importance of the gastric emptying, especially for the absorption of the drugs classified into Class I of Biopharmaceutics Classification System, 64) has already been pointed out by human study, where the irregular shapes of the absorption rate and of the plasma concentration-time profiles were evidenced to be determined by the gastric emptying profile. 60) On the other hand, there is no significant difference in AUC values between both food conditions ( Table 9 ). As reported previously, 38, 39, 42) AUC, an extent of bioavailability, is not affected by the delay of the GI transit in the case of a well-absorbable drug like as theophylline, because it is almost completely absorbed even under the condition where GI transit is fast such as the fasted condition.
The GI transit parameters in each subject can be estimated without accompanying affliction using a gamma scintigraphic technique. Using the segmental absorption data in rats, which can be easily obtained experimentally or from literatures, and the pharmacokinetic parameters after intravenous administration in human, which can also be obtained through literature reference, the plasma concentration profile for the concerned drug in the individual would be predicted with the corresponding GI transit condition, although further studies for drugs with absorption characteristics different from that of theophylline must be necessary. 65, 66) From our studies using GI-transit retarded rats and the analyses based on GITA model, it has been clearly shown that the absorption of a poorly absorbable drug should be improved by the increase in the residence time of drug in GItract. We have also developed poly(vinyl alcohol)-gel spheres (PVA-GS) as an oral drug delivery system with characteristics of prolonging GI-transit time and controlling drug release. 65) As the use of bioadhesive polymer has been found to be essential in dosage forms developed to control the GI transit rate, [67] [68] [69] we modified PVA-GS using chitosan (CS) as one of such polymers. 66) CS is a natural polyaminosaccharide prepared from chitin by N-deacetylation with alkali. It has been used in biomedical and pharmaceutical fields because of its favorable properties of low toxicity and good biocompatibility. 70) Then, to investigate the effect of retardation of GI transit rate on drug absorption behavior, comparative studies were performed using two types of PVA-GS with chitosan (CS/PVA-GS) and without chitosan (PVA-GS). 66) The GI transit time of a dosage form is changed by many factors, among which the particle size is a very important factor. In both GSs used in the study, the particle size was less than 40 mm and nearly 45% of both GSs were in the 5-10 mm range. The average diameter showed no significant difference between PVA-GS and CS/PVA-GS: 7.36 and 7.38 mm, respectively, showing that the GSs made by our method without crosslinking agent are very small.
EVALUATION OF DOSAGE FORMS TO REGULATE GI TRANSIT RATE
In an in-vivo GI transit test using phenol red-containing GSs, PVA-GS reduced the GI transit rate and furthermore, CS/PVA-GS prolonged the small-intestinal transit time more than PVA-GS (Fig. 19) . 66) In this study, the small intestine was divided into four equal segments (about 20 cm each); we called the four segments SI1, SI2, SI3 and SI4 from the upper part, respectively. The small-intestinal transit of CS/PVA-GS was slower than PVA-GS, especially in the lower small intestine (phenol red recovery at 4.5 h in SI4 was 10.8% for PVA-GS and 27.3% for CS/PVA-GS), resulting in the delay for CS/PVA-GS to reach the large intestine (phenol red recovery at 4.5 h in the large intestine was 88.8% for PVA-GS and 65.7% for CS/PVA-GS). While the values of CLg i in the stomach for GSs were much smaller than that for solution (2.03 h Predicted AUCs were calculated from the data simulated by the convolution method based on the GITA Model. The prediction was performed using three different sets of weight function, i.e., pharmacokinetic parameters with the lowest plasma level, a) the ones averaged from the data of 24 subjects b) and the ones with the highest plasma level c) after intravenous administration of theophylline. The parameters were normalized at the dose of 1 mg/kg. 66) with permission from the Pharmaceutical Society of Japan.)
Since it was determined that CS/PVA-GS delayed the GItransit time more than PVA-GS, comparative studies were performed on the characteristics of drug absorption from the two types of gel spheres. Theophylline and ampicillin were used as model drugs. The two GSs showed similar release profiles and linear relations in Higuchi's plot were observed in both GSs up to 80% release, suggesting that diffusion in the gel-matrix is the rate-determining step for the drug release. Approximately 80% of theophylline was released in 4 h from both GSs. Figure 20A shows the plasma concentration-time profiles of theophylline following oral administration of PVA-GS and CS/PVA-GS containing aminophylline. GSs delayed the rise in the plasma concentration in comparison with the solution (T max , from 0.40 to 3.57 h; C max , from 10.1 to 4.4 mg/ml), and the plasma levels were kept relatively high for a longer period. However, the addition of CS did not affect the plasma concentration profile for PVA-GS. The pharmacokinetic parameters are listed in Table 10 . The extent of bioavailability was almost 1.0 in all the three dosage forms. The values of mean absorption time (MAT ) for the solution, PVA-GS and CS/PVA-GS were 0.30, 3.65 and 3.51 h, respectively. The different intestinal transit rates of the two GSs affected neither the rate nor the extent of bioavailability of rapidly absorbable theophylline, since not only the gastric emptying rates but also the drug releasing rates are similar in the two dosage forms.
Contrary to theophylline, the bioavailability of poorly absorbable ampicillin tended to be increased by the administration as the PVA-GS dosage form, which was significantly further enhanced by the addition of CS. As is in the case of theophylline, the release of ampicillin from both GSs was suggested to be determined by the diffusion in the gel-matrix. Approximately 80% of ampicillin was released in 4 h from both GSs. Figure 20B shows the plasma ampicillin levels following oral administration of PVA-GS and CS/PVA-GS, and the pharmacokinetic parameters are listed in Table  10 . When ampicillin was administered as the solution, approximately 70% of the dose was unabsorbed and entered the large intestine. The GSs increased the residence time in the small intestine, resulting in the increased bioavailability, and the addition of CS further increased the bioavailability significantly. MAT of ampicillin in CS/PVA-GS (4.28 h) was longer than that in PVA-GS (3.57 h), indicating that the antibiotic in the GS containing CS could be absorbed for a longer period than the GS without CS. Since the absorption of ampicillin is permeation-rate limited, the large amount of the antibiotic released from PVA-GS passes through the small intestine to the large intestine. The addition of CS prolonged the residence time of the GS in the small intestine and thus increased the period for the absorption of the poorly absorbable drug. This would be the reason for the enhanced bioavailability by CS/PVA-GS. The results clearly shows that CS/PVA-GS should be useful not only to extend the absorption time but also to improve the bioavailability of poorly absorbable drugs, which is a practical evidence as well that the prolongation of the residence time in the small intestine leads to the enhancement of bioavailability for poorly absorbable drugs.
In conclusion, we have developed GITA Model containing the GI transit, the absorption and the hepatic first-pass metabolism processes. Based on GITA Model, the analyses of the absorption kinetics of drugs with variable absorption characteristics clearly showed the importance of GI transit rate in determining the bioavailability of orally administered drugs. Furthermore, using GITA Model makes it possible to predict the drug absorption behavior, even the plasma con- 66) with permission from the Pharmaceutical Society of Japan.) 66) with permission from the Pharmaceutical Society of Japan.)
